Navigation Links
Novavax Reports Fourth Quarter and 2008 Year-End Financial Results
Date:3/31/2009

imarily to their illiquidity. Interest income for the year ended December 31, 2008 includes a $500,000 adjustment to related to the correction of the Company's accounting for the notes receivable with two former directors.

The loss from continuing operations was $10.6 million and $36.3 million for the fourth quarter and full year of 2008, respectively.

Income and losses from discontinued operations are a result of the Company's decision to discontinue manufacturing of Estrasorb. The Company recorded a loss from discontinued operations of $0.5 million in the fourth quarter of 2008 as compared to a loss of $2.8 million in the fourth quarter of 2007. The decreased loss of $2.3 million was principally due to the completion of the Graceway agreements. The Company recorded income from discontinued operations for the year ended December 31, 2008 of $0.3 million compared to a loss from discontinued operations of $6.2 million for 2007. In February 2008, the Company entered into an asset purchase agreement with Graceway, LLC providing for the sale of certain assets related to Estrasorb. The Company also entered into a supply agreement with Graceway which required the Company to manufacture additional units of Estrasorb. The Company delivered the additional units of Estrasorb and exited the facility in August 2008.

The total net loss when combining the loss from continuing and discontinued operations was $11.0 million and $36.0 million for the fourth quarter and full year of 2008, respectively.

As of December 31, 2008, the Company had $33.9 million in cash and investments (consisting of auction rate securities at their fair value) as compared to $46.5 million for the same period last year. The decrease of $12.6 million was principally due to operating losses incurred in 2008, partially offset by our equity financing of $17.5 million. Additionally, cash and short-term investments as of December 31, 2008
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Novavax Announces Release Date of 2007 Fourth Quarter, Full Year Financial Results and Investor Conference Call
2. Novavax CEO to Present at the Partnering for Global Health Forum
3. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
4. Novavax Announces Release Date of 2007 Third Quarter Financial Results and Investor Conference Call
5. Novavax and Allergan Terminate Manufacturing Supply Agreement for Estrasorb
6. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
7. Cadus Reports 2008 Results
8. Nephros Reports 2008 Fourth Quarter and Full Year Financial Results
9. Cardiogenesis Reports Fourth Quarter and Fiscal Year 2008 Results
10. Tiens Biotech Group (USA) Reports Record Twelve-Month Results
11. ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Tara Haelle HealthDay ... -- Measuring how quickly a child,s brain processes sounds ... a new study. Observing children,s brainwaves may ... possible, the study authors reported. "The finding that ... associated with autism severity is hugely promising," said senior ...
(Date:9/22/2014)... “The Race is On!” for the 22nd Susan G. ... 2014 as it moves to its new location at Cesar ... fundraising and awareness event for Susan G. Komen® Central and ... the Cure provides supporters of all ages an opportunity to ... in. , “Moving the Race to Cesar Chavez Plaza ...
(Date:9/22/2014)... Mich. Many parents whose kids participate in athletics ... education, but that,s not enough to ensure parents are ... University of Michigan C.S. Mott Children,s Hospital National Poll ... of the 912 parents of middle and high school ... education: , , 23% have read a brochure ...
(Date:9/22/2014)... step for securing critical information systems, such as ... have created a new approach to computer security ... a terminal and automatically logs them out when ... to use their terminal. , Dartmouth,s Trustworthy ... their findings at the IEEE Symposium ...
(Date:9/22/2014)... to laser weapons, the Office of Naval Research (ONR) ... Modern Day Marine exposition that will prepare Marines as ... , ONR program officers will be in Booth No. ... Corps Base Quantico, to discuss how their research contributes ... "fast, austere and lethal." , ONR,s Expeditionary Maneuver Warfare ...
Breaking Medicine News(10 mins):Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 3Health News:Some concussion education more useful than others, parents say 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 3Health News:Modern Day Marine: ONR features technology for marines of the future 2
... causes epileptic seizures, but researchers from Melbournes Howard Florey ... with the help of their newly developed genetically modified ... mutation based mouse model in the world that mimics ... Dr Steven Petrou and his team to understand the ...
... the University of Pennsylvania School of Medicine have found ... the prognosis of patients with head and neck cancers. ... of CANCER. , The belief that a patients psychological ... cancer is one that has been prominent among patients ...
... upbeat, less positive patients , , MONDAY, Oct. 22 (HealthDay ... how long a person with cancer will survive, a ... that among head and neck cancer patients, emotional health ... factor affecting prognosis. , "We anticipated finding that emotional ...
... Sold Exclusively by GE Healthcare Expands Company ... Offerings within Worldwide Hospital Market, ... CSCX ), a global leader in advanced cardiac monitoring,and ... and has begun full shipments of its new "crash ...
... a prescription NSAID (non-steroidal anti- inflammatory drug) treatment that can be applied directly to ... osteoarthritis pain ... in both the knees and the joints ... of the hands * Offers highly effective ...
... and Item finalize settlement agreement with Teva, ... 22 Astellas,Pharma Inc. ("Astellas"; headquarters: Tokyo; ... ("King"; NYSE: KG) and Teva,Pharmaceutical Industries Ltd. ... of Astellas, along with Item Development AB ...
Cached Medicine News:Health News:Childhood epilepsy research offers new hope for seizure control 2Health News:Penn researchers find emotional well-being has no influence on cancer survival 2Health News:Emotional State Doesn't Affect Cancer Survival 2Health News:Emotional State Doesn't Affect Cancer Survival 3Health News:Emotional State Doesn't Affect Cancer Survival 4Health News:Emotional State Doesn't Affect Cancer Survival 5Health News:Cardiac Science Announces Full Shipment of 'Crash Cart' Defibrillator 2Health News:Cardiac Science Announces Full Shipment of 'Crash Cart' Defibrillator 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 2Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 4Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 5Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 6Health News:Adenoscan(R) Patent Lawsuits Settled 2Health News:Adenoscan(R) Patent Lawsuits Settled 3Health News:Adenoscan(R) Patent Lawsuits Settled 4
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 ... signed an exclusive, global license agreement with Plasma ... of its proprietary plasma fractionation process. Concurrently, the ... its intention to strategically refocus and rebrand the ... to pursue a national listing for its common ...
(Date:9/22/2014)... cancer is the second leading cause of cancer death ... early - the problem is that too often it ... Education Council (PCEC), – a national organization committed ... screening –  is sponsoring its 25 th Annual ... Committed to encouraging men to take a ...
(Date:9/22/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a ... announced that study designs and progress from two of ... global Phase 3 clinical trial in relapsed/refractory soft tissue ... in small cell lung cancer, will be presented at ... being held September 26-30, in Madrid, Spain ...
Breaking Medicine Technology:Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 2PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTT/1P chairs are recommended for the ... room, static control, health care and ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... ergonomic chairs with concave seats ... support • Select options like ... and glides. • BTT/1P chairs ... environments: industry, education, laboratory, clean ...
Medicine Products: